You are here: Industry Insights > Merck & Co

News List

Merck & Co pens $340m pain drug deal with KCL and Wellcome pharmaphorum
March 12, 2019
Merck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new class of painkillers that could provide an alternative to opioids and their dangerous side-effects.
AZ/Merck & Co’s Lynparza delays spread of pancreatic cancer pharmaphorum
February 27, 2019
AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.
FDA extends review of Merck & Co’s Keytruda in lung cancer use pharmaphorum
December 24, 2018
US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company submitted new data.
AZ/Merck & Co get new US use for ovarian cancer drug pharmaphorum
December 21, 2018
After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and a first approval in China for its new anaemia drug.
MSD announced collaboration with Brazilian non-profit over development of dengue vaccine pharmafile
December 14, 2018
US firm Merck & Co have announced a collaboration with the Brazilian non-profit Instituto Butantan, with the intention of developing vaccines for mosquito-borne virus dengue fever.
Merck & Co begins US filing of Ebola vaccine pharmaphorum
December 11, 2018
Merck & Co has begun a rolling filing in the US of its Ebola Zaire vaccine, known as V920, after the FDA said it could represent a breakthrough in treatment.
Thank you, Ken Frazier, for Making pharma look good fiercepharma
August 21, 2017
The resignation of Merck CEO Ken Frazier, seen here with President Donald Trump during his time on the manufacturing council, has generated goodwill for Frazier, his company and the pharma industry.